Urokinase plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) are established independent biomarkers for high metastasis risk in breast cancer. In this study, we investigated the regulatory activity of (−)-epigallocatechin-3-gallate (EGCG) and its derivatives on uPA and PAI-1 expression and thereby their antimetastatic potential. EGCG showed only marginal effects on the uPA system and on the metastatic behavior of breast cancer cells (MDA-MB-231). However, the EGCG derivative 3e with a methyl-substituted carbonate substituent at the 4″-position showed potent inhibition of PAI-1 (62%) and uPA (50%) expression. The Ras-extracellular-signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-kinase (PI3K)/Akt/NF-κB pathways, which regulate uPA and PAI-1 expression, were also affected by 3e (25%, 45%, and 25% reduction, respectively). In line with these findings, substantial reduction in metastatic behavior of MDA-MB-231 cells, such as adhesion (40%), invasion (56%), and migration (40%), was observed in the presence of 3e. It is also noteworthy that, in MDA-MB-231 cells, 3e did not exert any beneficial effect on the expression of matric metalloprotein (MMP) 2 and 9, which indicates that the anti-metastatic activity of 3e in MDA-MB-231 cells is not related to its regulation of the expression of MMPs. Taken together, we have shown that the EGCG derivative 3e could suppress the metastatic behavior of MDA-MB-231 cells through regulation of uPA and PAI-1.
| INTRODUCTION
In breast cancer patients, the main cause of death is metastases at distant sites, not the primary tumor. However, it is not possible to accurately predict the risk of metastasis development, which necessitates new prognostic markers for breast cancer metastasis. The serine protease urokinase plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) are newly established independent biomarkers for breast cancer, and high protein levels of uPA and PAI-1 are associated with high metastasis risk (Foekens et al., 2000; Harbeck, 2002; Harbeck, Kates, & Schmitt, 2002; Jänicke et al., 2001; Konecny et al., 2001; Look et al., 2002) .
The metastatic cascade is initiated by the degradation of the extracellular matrix followed by the invasion of the surrounding host tissue by cancer cells; matrix metalloproteinases and uPA play key roles in this process (Andreasen, Kjoller, Christensen, & Duffy, 1997) .
uPA converts plasminogen to plasmin, which degrades matrix components to activate latent metalloproteinases and latent growth factors.
Interestingly, in addition to uPA, increased levels of its inhibitor PAI-1 were paradoxically also reported to be a prognostic marker in breast cancer patients (Jänicke, Schmitt, & Graeff, 1991) . However, it should be noted that, independent of its protease-inhibitory capacity, PAI-1 also has a role in cell migration (Andreasen et al., 1997) and promotes tumor invasion and angiogenesis (Bajou et al., 2004) .
Of the two markers, PAI-1 has been the focus of many studies, with numerous reports regarding PAI-1 inhibition with small molecules (Gomes-Giacoia, Miyake, Goodison, & Rosser, 2013; Gorlatova et al., 2007) , TM5001/TM5007 (Izuhara et al., 2008) , TM5257 (W. T. Huang, Vayalil, Miyata, Hagood, & Liu, 2012; Izuhara et al., 2010) , TM5441 (Boe et al., 2013; Pelisch et al., 2015) ], monoclonal antibodies (Fortenberry, 2013) , and aptamers (Blake, Sullenger, Lawrence, & Fortenberry, 2009; Brandal, Blake, Sullenger, & Fortenberry, 2011; Fortenberry, Brandal, Carpentier, Hemani, & Pathak, 2016; Madsen et al., 2010) . However, less attention has been paid to control the gene expression of uPA and PAI-1 and thus reduce their levels, which would serve to inhibit the metastasis of breast cancer cells.
Green tea polyphenols have been reported to block the invasive behavior of human breast cancer MDA-MB-231 cells by inhibiting the transcription factors for uPA (activator protein-1 and NF-κB [nuclear factor κB]) and by forming signaling complexes responsible for cell adhesion and migration (uPA, uPA-receptor, vitronectin, and integrin receptor; Slivova et al., 2005) . Figure 1 ], the major polyphenol in green tea, has also been reported to play an important role in inhibiting the invasive behavior of breast cancer (Kushima et al., 2009 ), but its direct relationship with uPA/PAI-1 levels has not yet been established. Thus, we aimed to evaluate the inhibitory potential of EGCG against the invasive behavior of MDA-MB-231 cells in conjunction with its effects on uPA and PAI-1 protein levels. Moreover, peracetylated EGCG [AcEGCG (2), Figure 1 ] (Chao et al., 2010; Chiou et al., 2013; Lambert et al., 2006; Landis-Piwowar et al., 2007; Wang et al., 2013) and AcEGCG derivatives with alkyl substituents at the D-ring 4″-position (3, Figure 1 ; Seo, Kim, Choo, & Chong, 2017) , which had been investigated to overcome low stability and high polarity of EGCG, were also included for biological assay.
Herein, we report the inhibition of the invasion, adhesion, and migration of human breast cancer MDA-MB-231 cells by treatment with EGCG (1), AcEGCG (2), and AcEGCG derivatives (3) through regulation of the expression of both uPA and PAI-1.
| MATERIALS AND METHODS

| Chemicals and reagents
(−)-EGCG (1) is the product of Xi'an Le Sen Bio-Technology Co., Ltd.
(China). AcEGCG (2) and its derivatives (3) were prepared according to previous methods (Seo et al., 2017 ; Scheme 1). Briefly, AcEGCG (2), obtained from the reaction of EGCG with excess amount of Ac 2 O in pyridine, was directly converted to desired 4″-O-alkylated AcEGCG (3a-3j) upon treatment with appropriate alkyl halide in the presence of KI and K 2 CO 3 (5-40% yield; spectroscopic data can be found in Supporting Information).
Dimethyl sulfoxide (DMSO) and MTT [(3-(4,5-dimethylthiazol-2-yl 
| Cell culture
Human breast cancer MDA-MB-231 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI-1640 medium, supplemented with 10% FBS, penicillin (100 units/ml), and streptomycin (100 μg/ml), at 37°C with 5% CO 2 in a humidified atmosphere. Technology), respectively, were used. Western blotting protocols were as described above.
| NF-κB expression
NF-κB protein in MDA-MB-231 cells was isolated using a cytoplasmic and nuclear proteins lysis buffer, which consisted of nuclear extract lysis buffer (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 25% glycerol, 1× protease inhibitors) and cytoplasmic extract (CE) lysis buffer . The supernatant, that is, the nuclear extract, was harvested. NF-κB protein was detected by immunoblotting using NF-κB rabbit monoclonal antibody (Cell Signaling Technology). Western blotting protocols were as described above.
| Cell invasion assay (trans-well invasion assay)
Cell invasion was analyzed using a Transwell ( Taken together, 3e was found to be the most promising compound with PAI-1 modulating activity. The EGCG derivative 3e
showed concentration-dependent PAI-1-reducing activity (Figure 3a) and, at optimal concentration of 30 μM, it reduced PAI-1 expression by 62% compared with the control (Figure 3b ). Compound 3e was also evaluated for its inhibitory activity against PAI-1, but it did not inhibit PAI-1 activity at 30 μM (data not shown). The selected AcEGCG derivative 3e was then investigated for its effect on reducing uPA levels in MDA-MB-231 cells (Figure 3c ). At 30 μM, compound 3e showed 50% reduction in uPA level, but other compounds including EGCG (1) and
AcEGCG (2) were not effective.
| Treatment of MDA-MB-231 cells with AcEGCG derivative 3e results in diminished protein levels associated with the uPA system (2): Reduction of phospho-ERK, phospho-p38 AMPK, and NF-κB levels
The Ras-extracellular-signal-regulated kinase (ERK), p38 MAPK, and expression of NF-κB, but AcEGCG (2) and its derivative 3e showed significant attenuation of the levels of phospho-ERK, phospho-p38 MAPK, and NF-κB, with 3e being more effective than 2 (Figure 4) .
Thus, MDA-MB-231 cells treated with 3e exhibited reduced phospho-ERK and phospho-p38 MAPK levels by 25% and 45%, respectively (Figure 4a,b) . A similar trend was observed for NF-κB level in the breast cancer cells treated with 3e, which resulted in 25% reduction (Figure 4c ).
The effect of 3e on the expression of NF-κB was further demonstrated by addition of betulinic acid (BetA; 10 μM), an activator of NF-κB (Kasperczyk et al., 2005) , to the incubation mixture ( Figure 5 ).
Upon addition of BetA, the level of NF-κB was shown to increase by 130% in the DMSO control ( Figure 5 ). In the case of 3e, the reduced NF-κB expression was rescued to 100% of the control by BetA ( Figure 5 ).
| Inhibition of uPA/PAI-1-promoted metastatic behavior of MDA-MB-231 cells by 3e
Metastasis is the cumulative result of multiple changes in tumor cells and their microenvironment that enables cellular migration and invasion into healthy host tissue. As proliferating neoplastic cells attempt to escape the primary tumor site, local cell adhesion and invasion of the surrounding tissue must occur (Friedl & Alexander, 2011) . Effects of the EGCG derivatives on the metastatic behavior of MDA-MB-231 cells were evaluated. 
| Inhibition of cell adhesion
| Inhibition of cell invasion
The inhibition of the proteolytic activity of MDA-MB-231 cells by the EGCG derivatives was also determined by cell invasion assay. The cells were seeded on the vitronectin-coated filters in the presence of the EGCG derivatives, and the number of invaded cells was counted. Neither EGCG (1) nor AcEGCG (2) was effective in inhibiting cancer cell invasion to the vitronectin filter, but 3e showed visible reduction in the number of MDA-MB-231 cells to penetrate the filter (Figure 7a ).
The number of cells traversed was then counted to show that 3e effectively suppressed cell invasion (56% reduction compared with the control; Figure 7b ).
| Inhibition of cell migration
Cell migration is one of the characteristics of highly invasive MDA-MB-231 breast cancer cells, and the effects of the EGCG derivatives on cell migration was investigated by scratch wounding assay However, presumably, due to the differences in assay conditions, we were not able to reproduce the previous results and, at 30 μM of concentration, neither EGCG (1) nor AcEGCG (2) was found to modulate the expression levels of MMP-2 (Figure 9a ) and MMP-9 (Figure 9b ). On the contrary, a slight but subtle decrease (~20%) in the amount of MMP-2 and MMP-9 was observed in the presence of 3e (Figure 9a,b) . Considering the fact that the uPA system activates pericellular proteolysis (Breuss & Uhrin, 2012) , this result indicates that the anti-metastatic activity of 3e in the metastasis-probe MDA-MB-231 cells is also related albeit partially to its regulation of the expression of MMPs.
| DISCUSSIONS
Metastasis, a process whereby cancer cells spread from a primary site to distant organs, is responsible for most cancer-related deaths. Therapeutic strategies against cancer metastasis have thus been intensively explored, and EGCG has been highlighted due to its possible cancerpreventive activity and inhibition of multiple signaling pathways EGCG has been reported to inhibit multiple proteins involved in the invasiveness of cancer cells including vascular endothelial growth factor (Neuhaus et al., 2004) and MMPs (Fassina et al., 2004) . High protein levels of uPA and PAI-1 are also associated with high metastasis risk, and EGCG is known to inhibit uPA in vitro (Jankun, Selman, Swiercz, & Skrzypczak-Jankun, 1997) and TNF-α-induced PAI-1 (Cao et al., 2013) . Nevertheless, in metastasis-prone breast cancer cells, the anti-metastatic activity of EGCG in relation to inhibition or downregulation of uPA and PAI-1 has only rarely been scrutinized (Slivova et al., 2005) . Also, uPA and PAI-1 are gaining more and more attention as biomarkers for metastasis-prone breast cancer. Thus, uPA/PAI-1-targeted anti-metastasis activity of EGCG in breast cancer cells deserves intensive investigation.
MDA-MB-231 breast cancer cell lines are known to frequently and reliably metastasize to distant organs (Iorns et al., 2012) . In this study, we evaluated inhibitory activity of EGCG and AcEGCG against uPA/ PAI-1 and metastatic behavior of MDA-MB-231 cells, but they showed only marginal effects. We reasoned that the low bioactivity of EGCG and AcEGCG might be attributable to their low stability, and novel EGCG derivatives (3a-3h) with various functionalities at 4″-O position were prepared (Figure 1) . The EGCG derivatives (3a-3h) were then evaluated for their effects on downregulation of PAI-1 and, among those, compounds 3c, 3d, and 3e that have an ester or a carbonate functionality at 4″-O position showed specific PAI-1-reducing activity (Figure 3 ). Considering the hydrolysable nature of an ester or a carbonate linkage, it might be assumed that the PAI-1-reducing 3c, 3d, and 3e might have behaved as EGCG prodrugs. Particularly, the methylsubstituted carbonate 3e showed the most promising properties in terms of toxicity and PAI-1-reducing activity, and 3e was further investigated for its potency as anti-metastasis agent in breast cancer cells.
The EGCG derivative 3e showed concentration-dependent PAI-1-reducing activity (Figure 3a) , and at optimal concentration of 30 μM, it reduced PAI-1 expression by 62% compared with the control (Figure 3b) . Also, at 30 μM, 3e showed 50% reduction in uPA level (Figure 3c ). To our knowledge, 3e is the first example that potently 
| CONCLUSIONS
The uPA system has been recognized to facilitate tumor invasion and development of metastases in breast cancer. As a result, there have been many efforts to inhibit uPA and PAI-1-related signaling pathways, and inhibitors of PAI-1 showed potent anti-metastatic activity.
In this study, based on the previously reported inhibitory activity of EGCG on the invasive behavior of breast cancer, we focused on the regulatory effect of EGCG on uPA/PAI-1 levels and thereby antimetastatic activity in MDA-MB-231 cells. In addition, to tackle the well-known physicochemical problems of EGCG such as instability and high polarity, several derivatives including AcEGCG and its D-ring 4″-substituted congeners were included in bioassay. Interestingly, EGCG and AcEGCG showed only the marginal effects on the uPA system and the metastatic behavior of MDA-MB-231 cells, but the AcEGCG derivative 3e with a methyl-substituted carbonate at the 4″-position showed potent inhibition of PAI-1 (62%) and uPA (50%) expression. The Ras-ERK, p38 MAPK, and PI3K/Akt/NF-κB pathways, which are suggested to participate in invasive breast cell migration by regulating uPA and PAI-1 expression, were also affected by 3e (25%, 45%, and 25% reduction, respectively). In line with these findings, substantial reduction in metastatic behavior of MDA-MB-231 cells, such as adhesion (40%), invasion (56%), and migration (40%), was observed in the presence of 3e. It is also noteworthy that, in MDA-MB-231 cells, EGCG (1), AcEGCG (2), and 3e did not exert any beneficial effect on the expression of MMP-2/9, which indicates that the anti-metasta- 
